ReviewCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2002
New insights into the mechanisms and management of atrial fibrillation.
Review in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat.British journal of clinical pharmacology · 2005Pooled it
- Antiarrhythmic and electrophysiologic effects of flecainide on acutely induced atrial fibrillation in healthy horses.Journal of veterinary internal medicine · 2015Trial
- Sex Differences in Presentation, Quality of Life, and Treatment in Chinese Atrial Fibrillation Patients: Insights from the China Atrial Fibrillation Registry Study.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Microelectrode array measurement of potassium ion channel remodeling on the field action potential duration in rapid atrial pacing rabbits model.International journal of clinical and experimental medicine · 2015Article
- Atrial Fibrillation in the Young: A Neurologist's Nightmare.Neurology research international · 2015Review
- The Use of Gene Therapy for Ablation of Atrial Fibrillation.Arrhythmia & electrophysiology review · 2014Article
- The role of the renin-angiotensin system blocking in the management of atrial fibrillation.Journal of drug assessment · 2012Article
- Effect of verapamil on tachycardia-induced early cellular electrical remodeling in rabbit atrium.Naunyn-Schmiedeberg's archives of pharmacology · 2007Article
- Digoxin and mortality in atrial fibrillation: a prospective cohort study.European journal of clinical pharmacology · 2007Article
- Atrial fibrillation: basic mechanisms, remodeling and triggers.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2005Review
- Role of atrial fibrillation threshold evaluation on guiding treatment.Indian pacing and electrophysiology journal · 2003Article
- Rhythm versus rate control for atrial fibrillation management: what recent randomized clinical trials allow us to affirm.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is a common contributor to cardiovascular morbidity and mortality. Two generally acceptable strategies exist for long-term AF management, with ongoing studies comparing the overall mortality associated with each. One strategy aims to maintain sinus rhythm, with antiarrhythmic agents if necessary, thereby preserving physiological cardiac electrical function but exposing the patient to the potential side effects of potent drugs. The second approach is to control the ventricular rate and prevent thromboembolic complications with anticoagulants, leaving the patient with AF. Both beta-blocking agents and calcium antagonists are more effective than digoxin in achieving rate control. Several nonpharmacological therapies including catheter ablation, implantable devices and surgical interventions show promise for rate control and maintenance of sinus rhythm. This paper provides an overview of new developments in pharmacological and nonpharmacological therapy. Key features of recently published clinical guidelines, including a unified classification scheme for AF and issues relating to rate control and maintenance of sinus rhythm, are considered. In addition, preliminary results from the recently presented AFFIRM study, the largest AF trial to date, are summarized. Finally, we discuss recent insights into the basic mechanisms underlying AF that have potentially significant clinical implications.
Indexed as
Identifiers
12403742PMC134179W2149003620What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.